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ABSTRACT 
 
Study Objectives. People with insomnia complain of cognitive deficits in daily life.  Results 
from empirical studies examining associations between insomnia and cognitive 
impairment, however, are mixed.  Research is needed that compares treatment-seeking 
and community-based insomnia study samples, measures subjective as well as objective 
cognitive functioning, and considers participants’ pre-insomnia cognitive function.   
Design and Participants. We used data from the Dunedin Study, a representative birth 
cohort of 1,037 individuals, to examine whether insomnia in early midlife was associated 
with subjective and objective cognitive functioning.  We also tested whether individuals 
with insomnia who reported seeking treatment for their sleep problems (treatment-
seekers) showed greater impairment than other individuals with insomnia (non-
treatment-seekers).  The role of key confounders, including childhood cognitive ability and 
comorbid health conditions, was evaluated. 
Measurements.  Insomnia was diagnosed at age 38 according to DSM-IV criteria. Objective 
neuropsychological assessments at age 38 included the WAIS-IV IQ test, the Wechsler 
Memory Scale, and the Trail-Making Test.  Childhood cognitive functioning was assessed 
using the Wechsler Intelligence Scale for Children-Revised (WISC-R) 
Results. A total of n=949 cohort members were assessed for insomnia symptoms and other 
study measures at age 38.  Although cohort members with insomnia (n=186, 19.6%) had 
greater subjective cognitive impairment compared to their peers at age 38, they did not 
exhibit greater objective impairment on formal testing. Treatment-seekers, however, 
exhibited significant objective impairment compared to non-treatment-seekers.  
Controlling for comorbidity, daytime impairment, and medications slightly decreased this 
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association.  Childhood cognitive deficits antedated the adult cognitive deficits of 
treatment-seekers.    
Conclusions.  Links between insomnia and cognitive impairment may be strongest among 
individuals who seek clinical treatment.  Clinicians should take into account the presence of 
complex health problems and lower premorbid cognitive function when planning 
treatment for insomnia patients. 
 
Key words: Insomnia, neuropsychological, cognitive 
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INTRODUCTION 
Cognitive complaints among people suffering from insomnia are common. 
Individuals with insomnia frequently self-report experiencing memory and concentration 
problems in their daily lives.1,2 Because acute sleep deprivation is strongly associated with 
acute deficits in memory and attention, it is plausible that sleep loss due to chronic 
insomnia could lead to longer-term cognitive impairment.3–5 Furthermore, the 
hyperarousal theory of insomnia6 suggests that the disorder is accompanied by increased 
physiological activation, which has been linked to poorer cognitive functioning.7–9  
Insomnia is the most common sleep disorder, affecting 10% to 20% of adults.10–13  The 
disorder’s high prevalence means that any cognitive impairment associated with it could 
pose major public health, economic, and/or safety burdens.10–12  Indeed, individuals with 
insomnia experience significantly higher rates of motor-vehicle and other unintentional 
fatalities, non-motor-vehicle accidents, and poor work productivity.10,14,15  These findings, if 
causal, suggest that successfully treating sleep difficulties such as insomnia might be one 
strategy to reduce the rising population burden of cognition-related health risks.16,17  
Empirical studies, however, have provided mixed evidence about the magnitude and 
functional significance of any differences in objective cognitive ability between individuals 
with versus those without insomnia.  For example, a meta-analysis of studies using mostly 
small clinical or volunteer-based samples concluded that individuals with insomnia 
exhibited mild to moderate impairment on objective measures of memory, problem 
solving, and attentional processes, although they did not exhibit impaired functioning on 
other objective cognitive tasks.18 To our knowledge, only one study has used a population-
based sample (a subset of adults aged >20 years from the Penn State cohort) to examine 
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this question.19  In contrast to findings from the meta-analysis, the Penn State cohort found 
that, overall, the presence of chronic insomnia was not associated with cognitive deficits – 
only insomniac individuals with objectively measured short sleep duration had any signs of 
impaired cognition.   
Inconsistencies in this literature may be resolved, in part, by examining whether 
individuals with insomnia drawn from community-based samples and those who self-refer 
for clinical attention differ with respect to their cognitive impairment.  These two groups 
may be different on a range of factors, including presence of psychiatric comorbidity, 
medical comorbidity, and severity of daytime impairment due to insomnia.13,20,21  All of 
these factors are known to influence health treatment-seeking decisions and to impair 
objectively measured cognitive functioning.13,22,23  Furthermore, objective 
neuropsychological test scores are imperfectly correlated with patients’ subjective 
complaints about cognitive difficulties, making it useful to examine both outcomes.  
Objective testing is designed to measure an individual’s maximum cognitive capacities 
under ideal performance conditions, whereas patients’ complaints may reflect difficulties 
they encounter in everyday life, under less-than-ideal conditions. 
Moreover, individual differences in objective cognitive functioning are known to 
emerge in childhood and be relatively stable over the lifecourse.24  It is therefore important 
to also consider individuals’ childhood cognitive ability when considering whether a health 
problem such as insomnia has affected their adulthood ability, to rule out the possibility 
that premorbid cognitive differences may better explain any observed associations 
between the health problem and objective cognitive functioning in adulthood.25 
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In this study, we made use of a large, population-based, representative cohort of 
adults to test whether individuals diagnosed with insomnia manifest impaired cognitive 
functioning, measured using both subjective cognitive assessments as well as a battery of 
standardized neuropsychological tests.  We then subdivided the insomnia cases into those 
who (a) reported seeking attention from a doctor or other professional for their sleep 
problems (henceforth labeled “treatment-seekers”) and those who (b) did not seek medical 
attention for their sleep problems (“non-treatment-seekers”).  We compared cognitive 
functioning between these two subgroups to examine whether treatment-seeking status 
may account for the heterogeneity of results in the earlier literature.  To assess whether 
key confounding factors explain any observed association between insomnia and cognitive 
functioning, we also sequentially controlled for concurrent psychiatric comorbidity, 
medical comorbidity, and daytime impairment due to insomnia.  Lastly, we controlled for 
study members’ childhood IQ to assess the role of premorbid differences in cognitive 
functioning. 
 
METHODS 
Sample 
Participants are members of the Dunedin Multidisciplinary Health and Development 
Study, a longitudinal investigation of health and behavior in a complete birth cohort.  Study 
members (N=1,037; 91% of eligible births; 52% male) were all individuals born between 
April 1972 and March 1973 in Dunedin, New Zealand, who were eligible for the 
longitudinal study based on residence in the province at age 3 and who participated in the 
first follow-up assessment at age 3.  The cohort represents the full range of socioeconomic 
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status in the general population of New Zealand’s South Island and is primarily white. 
Assessments were carried out at birth and at ages 3, 5, 7, 9, 11, 13, 15, 18, 21, 26, 32, and, 
most recently, 38 years, when 95% of the 1,007 study members still alive took part.  At 
each assessment wave, study members are brought to the research unit for a full day of 
interviews and examinations.  The Otago Ethics Committee approved each phase of the 
study and informed consent was obtained.    
 
Measures 
Insomnia diagnosis.  At the age-38 assessment in 2010-2012, study members were 
asked how often they had problems sleeping in the past month because they could not get 
to sleep within 30 minutes, woke up in the middle of the night, woke up in the early 
morning, or felt that their sleep was unrefreshing.26  Individuals were diagnosed with 
insomnia if they reported having at least one of the four sleep difficulties ≥3 times per 
week, and also reported that their sleep problems affected their lives ≥3 times per week in 
at least one of the following domains: (a) work, (b) ability to concentrate, (c) memory, (d) 
daytime sleepiness, (e) levels of energy or fatigue, or (f) levels of irritability,26 or (g) staying 
awake while driving, eating, or engaging in social activity.27,28  This definition meets the 
primary diagnostic criteria for insomnia according to the then-current Diagnostic and 
Statistical Manual of Mental Disorders-Version 4 (DSM-IV); however, we did not impose the 
DSM-IV exclusionary criteria (e.g., presence of comorbid conditions). 
Treatment-seeking for sleep problems.  At the age-38 assessment, study members 
were also asked whether there was any time during the past year when they wanted to talk 
to a doctor or other professional about their sleep difficulties, and whether or not they did 
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so.  Study members who met the diagnostic criteria for insomnia and who also reported 
talking to a doctor or other professional about their sleep problems were categorized as 
treatment-seeking.  All other study members with insomnia were categorized as non-
treatment-seeking.  (One study member who met criteria for insomnia was missing 
information on treatment-seeking, and was excluded from the analyses.) 
Cognitive functioning in adulthood.  We assessed study members’ adulthood 
cognitive functioning in two ways: Subjective assessments, comprising self-reported 
cognitive difficulties and informant-reported cognitive difficulties, and objective 
assessments, comprising tests of study members’ neuropsychological functioning.  All 
measures were assessed at age 38 years.   
For self-reported cognitive functioning, study members were queried about 
experiencing problems related to memory and attention.  Study members reported how 
often in the past year (never, sometimes, or often) they experienced problems with, e.g., 
keeping track of appointments, remembering why they went to a store, and repeating the 
same story to someone, among other items.  Scores on each of the 19 questions were 
summed to create an overall measure of cognitive difficulties (score range = 0 to 31; mean 
(SD) = 9.1(5.3); internal consistency reliability = 0.83). 
For informant reports, study members nominated people who knew them well. 
These informants were mailed questionnaires and asked to complete a checklist, including 
whether the study members had problems with their attention and memory over the past 
year (possible responses for each problem included “doesn’t apply,” “applies somewhat,” or 
“certainly applies” to the study member).29  The informant-reported attention problems 
scale consisted of four items: The study member “is easily distracted, gets sidetracked 
9 
 
easily,” “can’t concentrate, mind wanders,” “tunes out instead of focusing,” and “has 
difficulty organizing tasks that have many steps” (range = 0 to 8; mean(SD) = 0.93 (1.21); 
internal consistency reliability = 0.79). The informant-reported memory problems scale 
consisted of three items: “has problems with memory,” “misplaces wallet, keys, eyeglasses, 
paperwork,” and “forgets to do errands, return calls, pay bills” (range = 0 to 6; mean (SD) = 
0.72 (0.91); internal consistency reliability=0.63). 
For objective assessments of adulthood neuropsychological functioning, we used 
tests of IQ, executive function, learning and memory, and processing speed.   Full-scale IQ 
and its component index scores for working memory, processing speed, perceptual 
reasoning, and verbal comprehension were measured using the WAIS-IV.30  These scores 
have standardized M=100 and SD=15.  Additional tests of learning and memory, executive 
function, and processing speed included the Rey Auditory Verbal Learning Test,31 subtests 
of the Wechsler Memory Scale-III,32 the Trail-Making Test,33 and subtests of the Cambridge 
Neuropsychological Test Automated Battery (CANTAB).34  For these tests, the sample is a 
representative birth cohort and therefore formed its own norms.  Supplemental Table 1 
provides further details about each test.  All testing occurred in the morning in two 50-min 
counterbalanced sessions.   
Full-scale IQ score was negatively correlated with self-reported cognitive difficulties 
(r=-0.152, p<0.0001), informant-rated attention problems (r=-0.261, p<0.0001), and 
informant-rated memory problems (r=-0.139, p<0.0001). 
Confounding factors.  Social class at age 38 was assigned based on the study 
member's current or most recent occupation.35  The scale places each occupation into one 
of six categories based upon the educational levels and income associated with that 
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occupation in data from the New Zealand census.  The scale ranges from 1 = "unskilled 
laborer" to 6 = "professional."  For study members not currently in the labor force, age 32 
occupation was used (n = 37).  
Psychiatric conditions were assessed at age 38 in private standardized interviews 
using the Diagnostic Interview Schedule,36 with diagnoses made following the then-current 
DSM-IV criteria.37  Psychiatric comorbidity was defined using an ordinal covariate that 
indexed how many of the following psychiatric diagnoses the study member received at 
age 38 (0, 1, 2, 3, or 4+): depression, generalized anxiety disorder (GAD), post-traumatic 
stress disorder (PTSD), any fear or phobia (including panic disorder, social phobia, 
agoraphobia, and simple phobia), alcohol dependence, cannabis dependence, hard drug 
dependence, or research diagnoses of lifetime schizophrenia.38  
Medical comorbidity was assessed using a variable that indexed how many physical 
health conditions the study member reported at age 38 (observed range: 0 to 4; mean (SD): 
0.62 (0.80)).  Health conditions were chosen to include those that can predict both 
insomnia and cognitive impairment: asthma, obesity, hypertension, type 1 or 2 diabetes, 
arthritis, cancer, Crohn's disease, hepatitis C, lupus, and multiple sclerosis.  Study members’ 
asthma was defined by a positive response to “Has a doctor ever told you that you have 
asthma?” as well as self-reported presence of asthma symptoms in the past year (including 
recurrent wheezing, asthma attack, or treatment for asthma).  Obesity was defined as a 
body mass index (BMI; kg/m2) of 30 or higher; study members’ heights were measured 
using a portable Harpenden Stadiometer (Holtain, Crymych, United Kingdom) and their 
weights were recorded to the nearest 0.1 kg using calibrated scales.  Hypertension was 
defined as systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg.8,39  
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Diabetes was defined by HbA1c values ≥6.5%.40  Presence of other conditions was self-
reported. 
Medication use was measured with two variables.  Psychotropic medication use 
indexed whether the study member was currently taking any antianxiety, antipsychotic, 
antidepressant, antihistamine, or attention-deficit hyperactivity disorder medication 
(queried on the day of the study assessment at age 38).  These medications are known to 
impair cognitive functioning and may also interfere with sleep.  Sleep medication use was 
assessed separately as part of the age-38 sleep interview.  Study members were asked “In 
the past month, how often have you taken medicine (prescribed or over-the-counter) to 
help you sleep?” Those who reported taking such medicine at least once a week were 
classified as currently using sleep medication.  
Daytime impairment due to insomnia was indexed using a score of how many 
domains of persistent non-cognitive impairment study members experienced as a result of 
their sleep problems (i.e., their ability to work, daytime sleepiness, levels of energy or 
fatigue, level of irritability, or ability to stay awake while driving, eating, or engaging in 
social activity)41 (range = 0 to 5; mean(SD) = 0.40(0.93)). 
Study members’ cognitive functioning in childhood was measured using their full-
scale IQ scores, assessed at ages 7, 9, and 11 years using the Wechsler Intelligence Scale for 
Children-Revised (WISC-R).42  Scores were averaged across the three assessments, with a 
mean of 100 and a standard deviation of 15. 
 
Statistical Analysis 
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We used linear regression analyses to model the relationship between insomnia and 
subjective and objective measures of study members’ cognitive functioning, all at age 38.  
Subjective cognitive functioning outcome variables included scores on the self-reported 
cognitive difficulties scale and the two informant-reported cognitive (memory and 
attention) difficulties scales.  Objective cognitive functioning outcome variables included 
scores on the WAIS-IV IQ and the other tests of executive function, memory, and processing 
speed.  This first analysis controlled for study members’ sex and age-38 socioeconomic 
status (SES).     
We then excluded all those without insomnia from the analyses, and examined 
whether treatment-seeking (yes vs. no) predicted cognitive performance scores among 
study members with insomnia.  Model 1 for this subgroup analysis controlled for sex and 
SES.  Model 2 additionally controlled for psychiatric comorbidity, medical comorbidity, and 
medication use at age 38.  Model 3 additionally controlled for daytime impairment due to 
insomnia.  Lastly, Model 4 included all covariates from Models 1-3 and added a control for 
study members’ childhood cognitive functioning.  All statistical analyses were conducted 
using Stata 12.0 (StataCorp LP). 
 
RESULTS 
Of the n=949 Dunedin cohort members assessed at age 38, nearly one-fifth (19.6%, 
n=186) met diagnostic criteria for insomnia.  Of the n=185 study members with insomnia 
and information on treatment-seeking, 79.5% (n=147; 15.5% of the cohort) did not report 
seeking any treatment for their sleep problems in the past year; the remaining 20.5% 
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(n=38; 4.0% of the cohort) reported seeking treatment from a doctor or other professional 
for their sleep problems.   
We first examined whether study members diagnosed with insomnia evidenced 
subjective and objective cognitive impairment compared to good sleepers, controlling for 
sex and SES (Table 1).  Study members with insomnia scored higher on all three measures 
of subjective cognitive impairment (all p<0.01), indicating that both the insomniac study 
members themselves, as well as their informants, believed that their memories and 
attention were worse compared to good sleepers’.  However, these results were not 
corroborated by their performance on objective measures of cognitive function.  Scores on 
the full-scale IQ test, IQ subtests, Wechsler Memory Scale, Trail-Making Test, and the 
CANTAB were statistically and substantively indistinguishable between study members 
with and without insomnia (all p>0.10).  The only exception was the Rey Auditory Verbal 
Learning delayed recall memory task, on which the insomnia group performed slightly but 
significantly worse compared to good sleepers (p<0.05). 
We then examined whether cognitive functioning among treatment-seeking study 
members with insomnia differed from that of non-treatment-seeking study members with 
insomnia.  Columns 2 and 3 in Table 2 show mean scores on all cognitive functioning 
measures in these two insomnia subgroups.  Results (Table 2, Model 1) show that after 
controlling for sex and SES, treatment-seekers scored higher than non-treatment-seekers 
on the three subjective measures of cognitive problems: Self-reported cognitive difficulties 
(B=2.12, p=0.055), informant-reported attention problems (B=0.74, p=0.002), and 
informant-reported memory problems (B=0.37, p=0.036).   
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The treatment-seeking insomnia group also evidenced statistically greater cognitive 
impairment on several objective measures of functioning.  Their average unadjusted full-
scale IQ score was 10 points lower than non-treatment-seekers’ (mean=91.4 vs. 
mean=101.1; Model 1 B= -7.44, p=0.001).  Treatment-seekers did not exhibit impaired 
function on tasks related to executive functioning and memory, with the exception of the 
CANTAB Visual Paired Associates Learning task.  On this test of episodic memory and new 
learning, treatment-seekers made nearly twice as many errors compared to non-treatment-
seekers (unadjusted means=21.8 vs. 11.9; Model 1 B=8.25, p=0.029).  Treatment-seekers 
scored more poorly on the WAIS-IV processing speed index (unadjusted means=93.8 vs. 
101.8, Model 1 B= -6.77, p=0.000) but not on the CANTAB reaction time test (another 
measure of processing speed).  On the tasks related to perceptual reasoning, treatment-
seekers scored 6 IQ points lower than non-treatment-seekers, but this analysis did not 
reach conventional levels of statistical significance (Model 1 B= -4.74, p=0.07).  Lastly, 
treatment-seekers’ scores on the verbal comprehension index were nearly 11 points lower 
than non-treatment-seekers’ (unadjusted means=92.3 vs. 102.0; Model 1 B= -8.28, 
p<0.001).   
As noted previously, treatment-seeking individuals with insomnia may differ from 
those who do not seek treatment on a range of factors, including psychiatric and medical 
comorbidity, medication use, and daytime impairment.  Table 3 shows descriptive 
statistics for these variables among both treatment-seeking and non-treatment-seeking 
Dunedin study members with insomnia (as well as in good sleepers, for purposes of 
comparison).  When compared to non-treatment-seekers, treatment-seekers had 
significantly higher levels of psychiatric comorbidity (z=4.43, p<0.001), increased rates of 
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psychotropic and sleep medication use (both p<0.001), and more domains of non-cognitive 
impairment arising from their insomnia (z=2.54, p=0.011).  Treatment-seekers also 
reported experiencing marginally more medical comorbidity (z=1.80, p=0.071). 
Table 2 results for Models 2 and 3 show that controlling for comorbidity, 
medication use, and daytime impairment completely explained group differences in 
subjective cognitive functioning.  These factors also partially accounted for differences in 
objective measures of cognitive functioning, although the effect estimates for treatment-
seeking remained large and statistically significant in most cases.  We calculated the 
percent reduction in effect estimate magnitudes, averaging across all objectively measured 
cognitive performance tests from Model 1 to Model 3; the mean reduction in magnitude 
was 44%.  Thus, while higher levels of comorbidity, medication use, and daytime 
impairment account for a proportion of the objective cognitive impairment observed from 
testing treatment-seekers, these factors do not explain the entire association. 
Table 3 also indicated that treatment-seekers had lower IQ scores in childhood 
compared to non-treatment-seekers (mean=93.47 vs. mean=100.42, p=0.007).  In analyses 
additionally controlling for this childhood IQ variable (Table 2, Model 4), effect estimates of 
treatment-seeking status on adulthood cognitive functioning were substantially reduced 
and became non-significant, except in the case of verbal comprehension.  Figure 1 depicts 
childhood and adulthood full-scale IQ scores for treatment-seekers, non-treatment-seekers, 
and cohort members without insomnia.  The figure shows that study members who sought 
treatment for insomnia exhibited impaired cognitive functioning in adulthood largely 
because they started out life already suffering from cognitive deficits.  Lastly, we wanted to 
ensure that our results were not confounded by study members’ sleep problems earlier in 
16 
 
life, because children who sleep poorly may not do well on cognitive testing.  As children 
aged 5 to 9 years, a total of 106 study members (who took part in the age-38 assessment) 
had been reported by their mothers as having persistent sleep problems (16.2% of 
treatment-seekers (n=6), 9.4% of non-treatment-seekers (n=13), and 12.3% of cohort 
members without insomnia (n=87)).43 We re-estimated each model in Tables 1 and 2 with 
an additional covariate indexing the presence of persistent childhood sleep problems; 
results were largely unchanged (see Supplemental Tables 2 and 3). 
 
DISCUSSION 
Findings from cross-sectional study designs have suggested, albeit inconsistently, 
that individuals with insomnia suffer from impairments in cognitive functioning.18  Some 
data from the United States and elsewhere show that the population incidence of sleep 
problems, including insomnia symptoms, is rising with societal changes such as increasing 
rates of shift work and nighttime use of television and Internet-enabled devices.44–46  If 
insomnia does lead to cognitive deficits, these reports raise the possibility that insomnia-
related cognitive impairment – along with its associated threats to public health, such as 
unintentional injuries – will increase in the coming decades. 
However, data from our population-based cohort of 1000 adults suggest that at the 
community level insomnia is not associated with deficits in cognitive functioning.  Although 
individuals with insomnia (and people who knew those study members well) believed they 
suffered from significant memory and attention problems, this belief was not confirmed by 
impairment on objective measures of overall IQ, executive functioning, memory, processing 
speed, perceptual reasoning, or verbal comprehension.  We see two possible explanations 
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for this inconsistency.  On the one hand, it is already well-established that discrepancies 
exist between objective and subjective functioning among certain people with insomnia – 
for example, it has been repeatedly demonstrated that some individuals with insomnia 
perceive their average nightly sleep duration to be significantly shorter than it is when 
measured objectively using polysomnography (e.g., 47,48).  Discrepancies between objective 
and subjective functioning in insomnia may therefore extend to cognitive capacities, at 
least among the general population.  On the other hand, the inconsistency between 
objective and subjective performances may emerge from fundamental differences in 
measurement context.  While our neuropsychological testing sessions are designed to 
ensure that an individual can perform to his or her maximum ability (i.e., in a quiet room 
with no distractions), the study members’ self- and informant reports reflect everyday 
circumstances in which the study member may be fatigued, upset, or overwhelmed by 
multitasking. Our results provide reassuring evidence that insomnia does not lead to gross 
neuropsychological damage.  However, insomnia sufferers may notice that their attention 
and memory capacities deteriorate more acutely in situations where they are already 
cognitively vulnerable.   
Our finding that individuals with insomnia experienced worse subjective, but not 
objective cognitive functioning, is also in accordance with Harvey’s cognitive model of 
insomnia.49  This model suggests that insomnia sufferers may be excessively concerned 
about the consequences of their disorder, mistakenly believing that it will result in multiple 
problems in functioning.  Insomnia sufferers may also adopt behavioral techniques like 
imagery control to ameliorate their perceived functional problems; however, these 
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techniques can result in anxiety which in turn causes objective difficulties in daytime 
functioning.49   
Despite the absence of objective neuropsychological deficits among all study 
members with insomnia, we did find that a key subgroup – those who sought clinical 
treatment for their sleep problems – exhibited impaired cognition when compared to non-
treatment-seeking study members with insomnia.  Our finding that only a certain subset of 
those with insomnia showed poorer neuropsychological functioning is consistent with 
other literature on this topic.  For example, in another population-based study, Fernandez-
Mendoza et al. found that those with insomnia and objectively measured short sleep 
duration showed neuropsychological deficits, whereas those with insomnia and normal 
length sleep did not.19  Similarly, Edinger et al. found that only insomnia-diagnosed 
individuals with long sleep latency (a measure of physiological hyperarousal) experienced 
deficits in neuropsychological functioning.50  Harvey’s cognitive model could also be 
implicated: The treatment-seeking subgroup of our study members may have been 
particularly concerned about the impact of their symptoms, culminating in worse 
neuropsychological impairment. 
In our study, a remarkable 80% of adults reporting insomnia with significant life 
impairment had not consulted a doctor (even in New Zealand, which has a national health-
care system).  The 20% who were treatment-seekers tended to have other psychiatric and 
medical conditions, indicating that they were likely already engaged with medical 
specialists; this engagement may have facilitated their asking for help with insomnia.  
These figures reflect a high level of potential service need among community members 
suffering from insomnia.  Additional efforts to raise awareness about sleep-problem 
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treatment options and opportunities for reducing the public health burden of insomnia 
may be warranted. 
Treatment-seeking study members’ objective cognitive impairments were observed 
in their full-scale IQ scores as well as their scores on specific aspects of verbal 
comprehension, memory, and processing speed.  These specific domains of impairment, 
particularly memory and processing speed, are consistent with those found in previous 
studies.18,19  Mental abilities of working memory and processing speed are often termed 
“fluid” mental abilities,51 because they are known to be easily disrupted by acute factors 
such as illness and infection, intoxication, or severe fatigue.  Here insomnia is also 
implicated.  In contrast, verbal comprehension is termed a “crystallized” ability, which is 
usually established in childhood-adolescence and is difficult to disrupt thereafter, 
remaining stable into late life.  Treatment-seekers’ deficit in verbal comprehension may 
reflect, in part, a pre-insomnia level of cognitive vulnerability.   
Our study adds to the literature by showing that individuals who seek treatment for 
insomnia in adulthood already evinced diminished cognitive capacities in childhood.  
Premorbid differences in childhood cognitive functioning explained the vast majority of 
these treatment-seeking study members’ deficits in adulthood cognitive functioning.  These 
results suggest that treating insomnia patients for their sleep problems is not likely to 
alleviate their longstanding cognitive problems.  However, if clinicians can take insomnia 
patients’ cognitive problems into account when planning treatment, therapeutic outcomes 
may improve.  We observed that individuals in the treatment-seeking insomnia group had a 
mean IQ of 91, indicating that the individual’s ability to process information is weaker than 
that of 73% of the population.52  This degree of cognitive deficit may warrant some 
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adaptation of clinical treatment.53-57  Harvey and colleagues noted in a recent review that 
specific cognitive support strategies may enhance patients’ memory for the contents of 
therapy and their adherence to a treatment plan.53  Although cognitive behavioral therapy 
for insomnia (CBT-I) has already been shown to be effective,58,59 implementing such 
cognitive support strategies may improve CBT-I’s adoption and success rates. 
Although treatment-seekers also exhibited higher levels of psychiatric and medical 
comorbidity, medication use, and daytime impairment, accounting for these three factors 
only partially explained treatment seekers’ relative cognitive deficits.  It is widely 
acknowledged that cases of psychological disorder observed in clinical patient samples 
tend to be of longer duration and greater severity than cases observed in general 
population samples.21  Our finding that objective cognitive impairment is observed only 
among the treatment-seeking subgroup is in accordance with this principle.  Our study also 
underscores, however, that clinicians need to be aware that their insomnia patients may be 
struggling with neuropsychological impairment (as well as complex health conditions), and 
that they should factor that possibility into their clinical evaluations.  Patients may feel 
validated if clinicians acknowledge that patients in treatment for insomnia often struggle 
with problems of attention and memory.2,18  Certain cognitive abilities – e.g., working 
memory and problem solving – are necessary for carrying out complex tasks, and even mild 
impairment of these abilities may compromise individuals’ safety and work performance.   
Methodological advantages of the current study include its use of a population-
representative birth cohort, a rigorous operational definition of insomnia, a comprehensive 
battery of standard neuropsychological tests, and the inclusion of multiple raters as well as 
important confounding factors (such as comorbidity and medication use).  The study was 
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also strengthened by our measure of childhood IQ scores, which allowed us to examine the 
role of study members’ premorbid cognitive functioning when assessing the link between 
insomnia and cognitive functioning in adulthood.   
There were also several limitations to this study.  First, objective measures of our 
study members’ sleep habits (such as overnight sleep studies), as well as information on 
the presence of sleep disorders such as narcolepsy or sleep apnea, were not available and 
thus could not be incorporated into our analyses.  Additionally, our insomnia assessment 
did not include queries about the frequency of insomnia episodes (e.g., number of episodes 
in the past year), duration of current insomnia symptoms, or the age of onset of study 
members’ insomnia symptoms.  We therefore could not assess whether study members 
with longer-standing insomnia symptoms manifested greater cognitive impairment.19  
Furthermore, our categorization of study members with insomnia into treatment-seekers 
vs. non-treatment-seekers is based on self-report, and thus differs from previous studies 
using insomnia patients who sought treatment in a clinic. Finally, our data were right-
censored at age 38, and the relation between insomnia and neuropsychological function 
may differ in older groups.60   
Many adults reporting diagnosable insomnia likewise report cognitive complaints, 
but these cognitive complaints are confirmed by formal neuropsychological testing only in 
the smaller subset who are seeking a doctor’s help for insomnia.  This insight may help to 
resolve inconsistent findings in the literature on insomnia and cognition.  It is doubtful that 
insomnia causes cognitive decline in midlife adults; in our cohort of 38-year-olds, 
treatment-seeking individuals’ cognitive status had remained below the population 
average since their childhood.  Regardless of causality, clinicians treating individuals with 
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insomnia have the opportunity to acknowledge their patients’ cognitive complaints and 
address them.  Clinicians also have the opportunity to enhance the effectiveness of 
insomnia treatment for cognitively impaired patients if therapeutic communications are 
tailored to compensate for patients’ compromised verbal comprehension, slower mental 
processing speed, and impaired memory capacity.  Doing so may help to improve patients’ 
understanding and implementation of insomnia treatment, relieve their sleep problems, 
and reduce insomnia-related functional impairment.        
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Table 1. Subjective and objective cognitive functioning at age 38 in the Dunedin Study: Descriptive statistics and results of regression 
analyses comparing good sleepers to individuals with insomnia.  
 Cognitive performance scores  Regression model a 
 No insomnia 
(n=763)                         
Insomnia  
(n=186) 
 
Analysis compares individuals with 
insomnia to those without insomnia 
 Mean (SD)                          Mean (SD)                      B (SE) p 
Subjective cognitive functioning      
 Self-reported cognitive difficulties  8.50 (4.93) 11.29 (6.02)  2.60 (0.42) <0.001 
 Informant-reported cognitive problems: Attention 0.87 (1.15) 1.09 (1.30)  0.25 (0.10) 0.006 
 Informant-reported cognitive problems: Memory 0.66 (0.87) 0.88 (0.97)  0.24 (0.07) 0.001 
Objective cognitive functioning      
 WAIS-IV full IQ score (std) 100.34 (14.87) 99.07 (14.97)  -0.76 (1.08) 0.481 
Tests of executive functions      
 WAIS-IV Working memory index (std) 100.30 (15.02) 99.14 (14.64)  -0.50 (1.17) 0.670 
 WMS Months of Year Backward 3.05 (1.36) 3.23 (1.44)  0.11 (0.11) 0.291 
 Trail-Making Test B Time † 64.40 (20.24) 64.42 (23.23)  0.26 (1.66) 0.875 
 CANTAB Rapid Visual Information Processing A Prime  0.91 (0.05) 0.91 (0.05)  -0.0003 (0.004) 0.949 
Tests of memory      
 Rey Auditory Verbal Learning: total recall 37.63 (8.01) 36.98 (8.30)  -1.05 (0.60) 0.081 
 Rey Auditory Verbal Learning: delayed recall 9.24 (3.14) 8.88 (3.44)  -0.49 (0.25) 0.048 
 WMS Verbal Paired Associates: total recall 16.14 (8.58) 16.29 (8.44)  -0.02 (0.68) 0.978 
 WMS Verbal Paired Associates: delayed recall 5.23 (2.57) 5.34 (2.46)  0.05 (0.20) 0.813 
 CANTAB Visual Paired Associates Learning: total errors † 12.06 (17.01) 13.96 (20.87)  2.14 (1.46) 0.144 
Tests of processing speed      
 WAIS-IV Processing speed index (std) 100.18 (14.76) 99.98 (15.01)  -0.72 (1.14) 0.527 
 CANTAB Reaction Time: 5-Choice Reaction Time † 327.02 (47.27) 332.26 (54.95)  3.40 (4.06) 0.403 
Tests of perceptual reasoning      
 WAIS-IV Perceptual reasoning index (std) 100.39 (15.01) 98.46 (14.96)  -1.37 (1.17) 0.242 
Tests of verbal comprehension      
 WAIS-IV Verbal comprehension index (std) 100.11 (14.89) 99.76 (15.29)  0.28 (1.09) 0.796 
aLinear regression analysis predicting the cognitive performance scores from the insomnia diagnosis variable (yes vs. no), while controlling for sex and 
age-38 SES. Abbreviations: WAIS, Wechsler Adult Intelligence Scale; std, standardized score; WMS, Wechsler Memory Scale; CANTAB, Cambridge 
Neuropsychological Test Automated Battery.  
† On these tests, higher scores indicate slower performance or more errors, and thus worse functioning. 
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Table 2. Subjective and objective cognitive functioning at age 38 among the subset of cohort members with insomnia: Descriptive statistics and results 
of regression analyses comparing non-treatment-seeking individuals to treatment-seeking individuals.  
 Cognitive performance scores  Model 1 a Model 2 b Model 3 c Model 4 d 
 Insomnia,  
did not seek 
treatment   
(n=147) 
Insomnia,  
sought 
treatment  
(n=38) 
 
Analysis compares insomnia treatment-seekers to non-
treatment-seekers 
 Mean (SD) Mean (SD)  B (SE) B (SE) B (SE) B (SE) 
Subjective cognitive functioning        
 Self-reported cognitive difficulties  10.78 (5.83) 13.03 (6.46)  2.12 (1.10) 0.90 (1.18) 0.91 (1.20) 0.72 (1.22) 
 Informant-reported cognitive problems: Attention 0.93 (1.22) 1.72 (1.43)  0.74 (0.23) 0.37 (0.25) 0.30 (0.25) 0.23 (0.25) 
 Informant-reported cognitive problems: Memory 0.79 (0.94) 1.20 (1.03)  0.37 (0.18) 0.11 (0.19) 0.07 (0.19) 0.04 (0.19) 
Objective cognitive functioning        
 WAIS-IV full IQ score (std) 101.11 (14.88) 91.38 (13.01)  -7.44 (2.23) -6.62 (2.44) -6.56 (2.46) -2.66 (1.66) 
Tests of executive functions        
 WAIS-IV Working memory index (std) 100.15 (14.55) 95.17 (14.62)  -3.27 (2.45) -1.73 (2.64) -1.55 (2.67) 1.50 (2.33) 
 WMS Months of the Year Backward 3.35 (1.44) 2.76 (1.38)  -0.41 (0.23) -0.25 (0.25) -0.24 (0.25) -0.12 (0.25) 
 Trail-Making Test B Time † 63.12 (22.58) 69.22 (25.55)  4.31 (4.15) 4.47 (4.60) 3.15 (4.60) -0.82 (4.21) 
 
CANTAB Rapid Visual Information Processing A 
Prime  
0.92 (0.05) 0.90 (0.04) 
 
-0.01 (0.01) -0.01 (0.01) -0.01 (0.01) 0.001 (0.01) 
Tests of memory        
 Rey Auditory Verbal Learning: total recall 37.36 (8.26) 35.45 (8.45)  -1.10 (1.35) -1.47 (1.48) -1.63 (1.49) -0.66 (1.44) 
 Rey Auditory Verbal Learning: delayed recall 9.03 (3.35) 8.32 (3.80)  -0.51 (0.57) -0.50 (0.62) -0.46 (0.62) -0.27 (0.63) 
 WMS Verbal Paired Associates: total recall 16.49 (8.48) 15.63 (8.48)  -0.24 (1.51) -0.36 (1.66) -0.51 (1.67) 0.65 (1.59) 
 WMS Verbal Paired Associates: delayed recall 5.35 (2.49) 5.26 (2.41)  0.11 (0.44) -0.18 (0.48) -0.23 (0.48) 0.08 (0.47) 
 
CANTAB Visual Paired Associates Learning: total 
errors † 
11.87 (17.78) 21.81 (29.01) 
 
8.25 (3.74) 7.44 (4.09) 7.54 (4.14) 6.01 (4.16) 
Tests of processing speed        
 WAIS-IV Processing speed index (std) 101.75 (15.08) 93.77 (13.13)  -6.77 (2.58) -6.52 (2.82) -5.80 (2.82) -2.94 (2.53) 
 CANTAB Reaction Time: 5-Choice Reaction Time † 331.27 (57.04) 334.47 (46.71)  1.91 (10.16) -1.48 (11.03) -3.45 (11.11) -7.28 (11.19) 
Tests of perceptual reasoning        
 WAIS-IV Perceptual reasoning index (std) 99.71 (14.88) 93.54 (14.56)  -4.65 (2.52) -3.28 (2.77) -3.51 (2.79) -0.26 (2.33) 
Tests of verbal comprehension        
 WAIS-IV Verbal comprehension index (std) 102.01 (15.44) 91.32 (11.68)  -8.28 (2.25) -8.43 (2.48) -8.58 (2.51) -5.33 (2.03) 
aModel 1 controls for sex and age-38 SES.  bModel 2 controls for Model 1 covariates and psychiatric comorbidity, medical comorbidity, and medication use. cModel 
3 controls for Model 2 covariates and number of domains of non-cognitive impairment experienced as a result of sleep problems.  dModel 4 controls for Model 3 
covariates and full-scale childhood IQ score. Statistically significant differences (p<0.05) compared to non-treatment-seekers are highlighted in bold font. 
†On these tests, higher scores indicate slower performance or more errors, and thus worse functioning. 
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Table 3. Demographic characteristics, comorbidity, daytime impairment, and childhood cognitive functioning among the full Dunedin cohort as well 
as three cohort subgroups: individuals without insomnia, individuals with insomnia who did not seek treatment for their sleep problems, and 
individuals with insomnia who sought treatment for their sleep problems. 
 
Full sample 
(n=949) 
No insomnia 
(n=763)                         
Insomnia:  
Did not seek 
treatment  
(n=147)             
Insomnia:  
Sought treatment 
(n=38) 
p 
(comparing 
treatment-
seekers to non-
treatment-
seekers) a 
Demographic characteristics      
 Sex (n (%) female) 502 (48.4%) 362 (47.4%) 87 (59.2%) 22 (57.9%) 0.886 
 Socioeconomic status at age 38 (mean (SD)) 3.74 (1.43) 3.75 (1.42) 3.79 (1.48) 3.40 (1.50) 0.132 
Comorbidity (age 38)      
 
Number of comorbid psychiatric conditions (mean 
(SD)) 
0.62 (0.97) 0.49 (0.87) 0.95 (1.08) 1.82 (1.45) <0.001 
 
Number of comorbid physical health conditions 
(mean (SD)) b 
0.62 (0.80) 0.59 (0.78) 0.67 (0.86) 0.95 (0.93) 0.071 
 Psychotropic medication use (n (%)) 161 (16.9%) 110 (14.5%) 28 (19.1%) 19 (50.0%) <0.001 
 Sleep medication use (n (%)) 63 (6.6%) 40 (5.2%) 9 (6.1%) 12 (31.6%) <0.001 
Daytime Impairment (age 38)      
 
Domains of non-cognitive impairment due to sleep 
problems (mean (SD)) 
0.40 (0.93) 0.03 (0.19) 1.80 (1.05) 2.45 (1.27) 0.055 
Childhood cognitive functioning (ages 7-11)      
 Full-scale WISC-R IQ score (mean (SD)) 100.0 (15.0) 101.06 (13.85) 100.42 (14.44) 93.47 (16.48) 0.007 
aSignificance tests (derived from analysis of variance [ANOVA], Pearson 2, or Poisson z-tests) compare individuals with insomnia who did versus did not seek 
treatment for it. Data for the full sample and individuals with no insomnia diagnosis are shown for comparison purposes only.  
bNumber of physical health conditions (0, 1, 2, 3, or 4): asthma, obesity, hypertension, type 1 or 2 diabetes, arthritis, cancer, Crohn's disease, hepatitis C, 
lupus, and multiple sclerosis. 
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Figure 1. Mean full-scale IQ scores in childhood and adulthood, by cohort members’ 
insomnia diagnosis and treatment-seeking status. Error bars represent standard error 
of the mean. 
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